ORCID Profile
0000-0001-5979-8887
Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the Feedback Form.
Publisher: Wiley
Date: 08-1978
DOI: 10.1038/ICB.1978.54
Abstract: A two-step procedure for the isolation of pure lactoferrin from bovine tears is outlined. The amino acid composition of this lactoferrin resembles closely the amino acid composition of lactoferrin isolated from bovine milk.
Publisher: Springer Science and Business Media LLC
Date: 06-1987
DOI: 10.1007/BF01871228
Abstract: Skin surface lipid (SSL) film is a mixture of sebum and keratinocyte membrane lipids, protecting skin from environment. Its composition is unique for the high percentage of long chain fatty acids, and of the polyterpenoid squalene, absent in other human tissues, and in non-human Primates sebum. Here, the still incomplete body of information on SSL as mediators of external chemical, physical, and microbial signals and stressors is revised, focusing on the central event of the continuous oxidative modification induced by the metabolic activity of residential and pathological microbial flora, natural or iatrogenic UV irradiation, exposure to chemicals and cosmetics. Once alpha-tocopherol and ubiquinol-10 antioxidant defences of SSL are overcome, oxidation of squalene and cholesterol gives rise to reactive by-products penetrating deeper into skin layers, to mediate local defensive inflammatory, photo-protective, immune reactions or, at higher concentrations, inducing local but also systemic immune depression, ultimately implicating skin cancerogenesis. Qualitative modifications of SSL represent a pathogenetic sign of diagnostic value in dermatological disorders involving altered sebum production, like pytiriasis versicolor, acne, atopic or seborrheic dermatitis, as well as photo-aging. Achievements of nutriceutical interventions aimed at restoring normal SSL composition and homeostasis are discussed, as feasible therapeutic goals and major means of photo-protection.
Publisher: Springer Science and Business Media LLC
Date: 09-1982
DOI: 10.1007/BF00234411
Abstract: Methenamine salts are often used as an alternative to antibiotics for the prevention of urinary tract infection (UTI). This review was first published in Issue 1, 2002 and updated in Issue 4, 2007. To assess the benefits and harms of methenamine hippurate in preventing UTI. We searched the Cochrane Central Register of Controlled Trials (CENTRAL in The Cochrane Library), MEDLINE (from 1950), EMBASE (from 1980), reference lists of articles and abstracts from conference proceedings without language restriction. Manufacturers' of methenamine salts were contacted for unpublished studies and contact was made with known investigators.Date of last search: June 2012 Randomised controlled trials (RCT) and quasi-RCTs of methenamine hippurate used for the prevention of UTIs in all population groups were eligible. A comparison with a control/no treatment group was a prerequisite for selection. Two authors independently assessed study quality and extracted data. Statistical analyses were performed using the random effects model and the results expressed as risk ratio (RR) for dichotomous outcomes with 95% confidence intervals (CI). An exploration of heterogeneity and a detailed description of results, grouped by population, was undertaken. Thirteen studies (2032 participants) were included. Six studies (654 patients) reported symptomatic UTI and eight studies (796 patients) reported bacteriuria. Overall, study quality was mixed. The overall pooled estimates for the major outcome measures were not interpretable because of underlying heterogeneity. Subgroup analyses suggested that methenamine hippurate may have some benefit in patients without renal tract abnormalities (symptomatic UTI: RR 0.24, 95% CI 0.07 to 0.89 bacteriuria: RR 0.56, 95% CI 0.37 to 0.83), but not in patients with known renal tract abnormalities (symptomatic UTI: RR 1.54, 95% CI 0.38 to 6.20 bacteriuria: RR 1.29, 95% CI 0.54 to 3.07). For short-term treatment duration (1 week or less) there was a significant reduction in symptomatic UTI in those without renal tract abnormalities (RR 0.14, 95% CI 0.05 to 0.38). The rate of adverse events was low. Methenamine hippurate may be effective for preventing UTI in patients without renal tract abnormalities, particularly when used for short-term prophylaxis. It does not appear to work in patients with neuropathic bladder or in patients who have renal tract abnormalities. The rate of adverse events was low, but poorly described.There is a need for further large well-conducted RCTs to clarify this question, particularly for longer term use for people without neuropathic bladder.
Publisher: Springer Science and Business Media LLC
Date: 12-1984
DOI: 10.1038/BJC.1984.260
Abstract: A monoclonal antibody was prepared against DIDS, an inhibitor of anion transport, and used to compare the occurrence and distribution of DIDS-binding sites of tumorigenic and non-tumorigenic human somatic-cell hybrids. The monoclonal antibody (E8) was produced by the fusion of the mouse myeloma (NS-1) with mouse spleen cells and is of the IgG1 subclass. The apparent half-saturation of DIDS for HEp-2 cells is 16 microM and the reaction is rapid. The number of binding sites on tumorigenic and non-tumorigenic hybrid cells was the same. The DIDS-binding protein occurs homogeneously on all cells, a characteristic which distinguishes it from the possible tumour antigen recognised by the M/27 monoclonal antibody.
Publisher: Wiley
Date: 10-1985
DOI: 10.1038/ICB.1985.54
Abstract: An erythrocyte sialoglycoprotein common antigen has been identified by a monoclonal antibody. The antigen recognised by the JCS-2 antibody was determined by immunoprecipitation, Western blotting and partial amino acid sequencing. Western blot analysis of human erythrocyte ghost membranes separated on sodium dodecyl sulphate polyacrylamide gel electrophoresis shows that the sialoglycoprotein common antigen occurs on the alpha, beta, gamma and delta sialoglycoproteins, either in their monomeric or dimeric form and as the heterodimer in the case of alpha and delta. The N-terminal sequence of the antigen prepared by immunoaffinity chromatography of the Triton-X100 extract of human erythrocyte ghosts shows the first 9 residues to be identical to the known sequence of the MN blood group glycoproteins. The common epitope on the sialoglycoproteins resides on the oligosaccharide and contains sialic acid.
Publisher: Elsevier BV
Date: 02-1986
DOI: 10.1016/0006-291X(86)90389-X
Abstract: The kinetics of actin polymerization has been used to quantitate the relative levels of actin nucleating activity in extracts from a number of related tumorigenic and non-tumorigenic cells. The level of nucleating activity was significantly elevated in the tumorigenic compared with the non-tumorigenic cell extracts whether the results were expressed on the basis of per protein (2-3 fold increase) or per total endogenous cellular actin (3-4 fold increase). It is concluded that this activity is probably due to an actin filament capping/severing regulatory protein(s) and that this protein(s) may be, at least partially, responsible for the microfilament disruption observed in transformed cells.
Publisher: Elsevier BV
Date: 03-1990
DOI: 10.1016/0014-4827(90)90135-W
Abstract: The relative amounts of intracellular gelsolin were determined in a number of human somatic cell hybrids and parental cell lines which greatly differ in their microfilament organizations. In contrast to the disruptive effect of gelsolin on actin filament formation in vitro, there is a correlation between the degree of microfilament organization and the amount of gelsolin within these cell lines.
Publisher: Springer Science and Business Media LLC
Date: 06-1985
DOI: 10.1038/BJC.1985.119
Abstract: The fluorescent indicator of Ca2+ concentration, quin-2, has been used to measure the concentration of free Ca2+ in the cytoplasm of tumorigenic and non-tumorigenic human somatic cell hybrids. The cell hybrids were derived from the fusion of a HeLa derivative (D98 AH2) and normal human fibroblasts. The calcium concentration of the tumorigenic cell lines was 180 +/- 7nM and the level in the non-tumorigenic cells was 136 +/- 6nM. This difference was statistically highly significant (P less than 0.001). Control experiments are reported which show that the level of 3a2+ measured is not influenced by cell density or by the concentration of quin-2-tetra-(acetoxymethyl)ester used in these experiments. The possible implications of this elevated level of cytoplasmic calcium in tumorigenic cells are discussed.
Location: United Kingdom of Great Britain and Northern Ireland
No related grants have been discovered for Michael Banyard.